Skip to main content

Advertisement

Log in

Cervical Lymph Node Dissection for Metastatic Testicular Cancer

  • Urologic Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Introduction

Despite high response rates to systemic chemotherapy, 30% of patients with advanced stage testicular carcinoma will have extra-retroperitoneal residual masses that require resection. Most often, these are located in the lungs and mediastinum and neck. Limited data are available concerning the incidence, surgical management, and follow-up of neck metastasis arising from a testicular primary tumor.

Methods

We retrospectively reviewed all 665 patients who were referred to a tertiary referral center with the diagnosis of testicular cancer from January 1997 to June 2009 for the presence of cervical metastases. Patients who underwent concomitant surgical therapy were identified and analyzed. Clinical and pathological data were collected from patient records, including radiology and pathology reports. Furthermore, data on primary treatment strategy, chemotherapeutic regimens, timing of surgical procedures, complications, disease recurrence, and follow-up were collected.

Results

Twenty-six patients (4%) had cervical lymph node metastasis. The majority (n = 19) had multiple ERP sites. Nine patients (35%) underwent selective neck dissection: in six patients, this was indicated because of residual masses after chemotherapy, and in three patients, cervical masses represented a late and distant relapse of previously treated disease. Viable cancer cells were present in the resected specimen only in these three patients. Seven patients are currently without evidence of disease. Two patients died of disseminated disease.

Conclusions

Cervical lymph node metastases originating from testicular cancer are rare but are more commonly observed in patients with advanced stage disease. Selective neck dissection can be safely performed both after chemotherapy and in the case of recurrent disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. See WA, et al. Incidence and management of testicular carcinoma metastatic to the neck. J Urol. 1996;155(2):590–2.

    Article  CAS  PubMed  Google Scholar 

  2. Carver BS, Sheinfeld J. Management of post-chemotherapy extra-retroperitoneal residual masses. World J Urol. 2009;27:489–92.

    Google Scholar 

  3. Motzer RJ, et al. Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. J Urol. 1998;159(1):133–8.

    Article  CAS  PubMed  Google Scholar 

  4. McGuire MS, et al. The role of thoracotomy in managing postchemotherapy residual thoracic masses in patients with nonseminomatous germ cell tumours. BJU Int. 2003;91(6):469–73.

    Article  CAS  PubMed  Google Scholar 

  5. Weisberger EC, McBride LC. Modified neck dissection for metastatic nonseminomatous testicular carcinoma. Laryngoscope. 1999;109(8):1241–4.

    Article  CAS  PubMed  Google Scholar 

  6. Lee JT, Calcaterra TC. Testicular carcinoma metastatic to the neck. Am J Otolaryngol. 1998;19(5):325–9.

    Article  CAS  PubMed  Google Scholar 

  7. Zeph RD, et al. Modified neck dissection for metastatic testicular carcinoma. Arch Otolaryngol. 1985;111(10):667–72.

    CAS  PubMed  Google Scholar 

  8. Krege S, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol. 2008;53(3):478–96.

    Article  PubMed  Google Scholar 

  9. Krege S, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol. 2008;53(3):497–513.

    Article  PubMed  Google Scholar 

  10. Fizazi K, et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy: results from an international study group. J Clin Oncol. 2001;19(10):2647–57.

    CAS  PubMed  Google Scholar 

  11. Hartmann JT, et al. Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. Eur J Cancer. 1997;33(6):843–7.

    Article  CAS  PubMed  Google Scholar 

  12. Steyerberg EW, et al. Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumor. Prediction of histology. ReHiT Study Group. Cancer. 1997;79(2):345–55.

    Article  CAS  PubMed  Google Scholar 

  13. Oechsle K, et al. [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. J Clin Oncol. 2008;26(36):5930–5.

    Article  PubMed  Google Scholar 

  14. Cappiello J, et al. Shoulder disability after different selective neck dissections (levels II–IV versus levels II–V): a comparative study. Laryngoscope. 2005;115(2):259–63.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J. H. W. de Wilt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Vledder, M.G., van der Hage, J.A., Kirkels, W.J. et al. Cervical Lymph Node Dissection for Metastatic Testicular Cancer. Ann Surg Oncol 17, 1682–1687 (2010). https://doi.org/10.1245/s10434-010-1036-x

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-010-1036-x

Keywords

Navigation